{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:02:06Z","timestamp":1782802926005,"version":"3.54.5"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>This retrospective real-world study aimed to describe anticoagulant prescribing trends, particularly for factor Xa (FXa) inhibitors, bleeding events, and reversal agent use in pediatric patients to assess potential populations for clinical trials of the FXa inhibitor reversal agent andexanet alfa. Real-world health care data from the TriNetX Global Network and Optum\u2019s deidentified Clinformatics<jats:sup>\u00ae<\/jats:sup> Data Mart Database (CDM) were analyzed to identify patients aged &lt;18 years old who were prescribed a direct oral FXa inhibitor, warfarin, or low-molecular-weight heparins from 2007 through 2024 (TriNetX, N\u2009=\u200959,780) or 2023 (CDM, N\u2009=\u20096470). The only anticoagulants prescribed to children were warfarin and\/or low-molecular-weight heparins in 2007 and 2008 in TriNetX and from 2007 through 2010 in CDM. Prescriptions of the FXa inhibitor rivaroxaban increased from 0.4% (2009) to 18.0% (2023) in TriNetX and from 0.8% (2011) to 34.0% (2023) in CDM, with similar trends for apixaban. Relevant bleeding was reported in 9.4% of patients prescribed an FXa inhibitor in TriNetX;\u2009\u2264\u20090.1% of patients received andexanet alfa the day of a bleed. Among patients prescribed an FXa inhibitor,\u2009\u2264\u20090.1% in TriNetX and 0 in CDM received andexanet alfa the day of surgery. Direct oral FXa inhibitor use in children is growing, as is the potential for associated bleeds; however, reversal agent use is rare in this population. Given the possible unmet need and subsequent patient recruitment challenges, designing pediatric clinical trials of reversal agents requires innovative approaches.<\/jats:p>","DOI":"10.1371\/journal.pone.0323137","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:34:39Z","timestamp":1746725679000},"page":"e0323137","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulant prescribing trends, bleeding events, and reversal agent use in pediatric patients: A retrospective, real-world study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-2944","authenticated-orcid":true,"given":"Sofia","family":"D\u2019Abrantes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-6421","authenticated-orcid":true,"given":"Christoph","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Bjursell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ambery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Berggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8422-6071","authenticated-orcid":true,"given":"Ulrika","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"3","key":"pone.0323137.ref001","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-054649","article-title":"The continued rise of venous thromboembolism across US Children\u2019s Hospitals","volume":"149","author":"SH O\u2019Brien","year":"2022","journal-title":"Pediatrics"},{"key":"pone.0323137.ref002","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.09.016","article-title":"Development of a risk model for pediatric hospital-acquired thrombosis: a report from the children\u2019s hospital-acquired thrombosis consortium","volume":"228","author":"J Jaffray","year":"2021","journal-title":"J Pediatr"},{"issue":"8","key":"pone.0323137.ref003","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/aogs.14384","article-title":"Systemic hormonal contraception and risk of venous thromboembolism","volume":"101","author":"O Heikinheimo","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"8","key":"pone.0323137.ref004","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1055\/s-0041-1729886","article-title":"Venous thromboembolism in pediatric cancer patients with central venous catheter-a systematic review and meta-analysis","volume":"47","author":"RS Hansen","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"pone.0323137.ref005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3171\/2021.3.SPINE201981","article-title":"Association of venous thromboembolism following pediatric traumatic spinal injuries with injury severity and longer hospital stays","volume":"36","author":"BM Hauser","year":"2021","journal-title":"J Neurosurg Spine"},{"issue":"1","key":"pone.0323137.ref006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","article-title":"Management of thrombosis in children and neonates: practical use of anticoagulants in children","author":"P Monagle","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"pone.0323137.ref007","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MOP.0000000000000084","article-title":"Venous thromboembolism in critically ill children","volume":"26","author":"LA Polikoff","year":"2014","journal-title":"Curr Opin Pediatr"},{"issue":"11","key":"pone.0323137.ref008","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/CCM.0000000000005075","article-title":"Life-threatening bleeding in children: a prospective observational study","volume":"49","author":"JC Leonard","year":"2021","journal-title":"Crit Care Med"},{"key":"pone.0323137.ref009","author":"European Medicines Agency"},{"key":"pone.0323137.ref010","author":"US Food and Drug Administration"},{"key":"pone.0323137.ref011","author":"US Food and Drug Administration"},{"issue":"22","key":"pone.0323137.ref012","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"P Monagle","year":"2018","journal-title":"Blood Adv"},{"key":"pone.0323137.ref013","doi-asserted-by":"crossref","first-page":"932085","DOI":"10.3389\/fped.2022.932085","article-title":"Adverse events of DOACs in children","volume":"10","author":"A Bosch","year":"2022","journal-title":"Front Pediatr"},{"key":"pone.0323137.ref014","doi-asserted-by":"crossref","first-page":"860369","DOI":"10.3389\/fped.2022.860369","article-title":"Practical considerations for use of direct oral anticoagulants in children","volume":"10","author":"H Whitworth","year":"2022","journal-title":"Front Pediatr"},{"issue":"3","key":"pone.0323137.ref015","first-page":"305","article-title":"A review of warfarin dosing and monitoring","volume":"14","author":"M Kuruvilla","year":"2001","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"11","key":"pone.0323137.ref016","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1007\/s11606-022-07528-y","article-title":"Special considerations for women of reproductive age on anticoagulation","volume":"37","author":"T Azenkot","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"4","key":"pone.0323137.ref017","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1203\/01.PDR.0000155943.07244.04","article-title":"Reduced bone density in children on long-term warfarin","volume":"57","author":"C Barnes","year":"2005","journal-title":"Pediatr Res"},{"issue":"3","key":"pone.0323137.ref018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2352-4642(21)00343-6","article-title":"Direct oral anticoagulants for use in paediatrics","volume":"6","author":"J Jaffray","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"13","key":"pone.0323137.ref019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"A Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"pone.0323137.ref020","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"TL Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"pone.0323137.ref021","author":"European Medicines Agency"},{"key":"pone.0323137.ref022","author":"US Food and Drug Administration"},{"issue":"22","key":"pone.0323137.ref023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.021765","article-title":"Thromboprophylaxis for children post-fontan procedure: insights from the UNIVERSE Study","volume":"10","author":"BW McCrindle","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"pone.0323137.ref024","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"C Male","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"pone.0323137.ref025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"LR Brand\u00e3o","year":"2020","journal-title":"Blood"},{"key":"pone.0323137.ref026","author":"RB Payne","year":"2022"},{"issue":"24","key":"pone.0323137.ref027","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease","volume":"80","author":"MA Portman","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"pone.0323137.ref028","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0323137.ref029","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"JW Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0323137.ref030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"S Schulman","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0323137.ref031","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.clinthera.2021.09.021","article-title":"Real-world anticoagulant use and incidence of venous thromboembolism and major bleeding in children","volume":"43","author":"J Hardin","year":"2021","journal-title":"Clin Ther"},{"issue":"1","key":"pone.0323137.ref032","first-page":"1","article-title":"New agents for DOAC reversal: a practical management review","volume":"29","author":"K White","year":"2022","journal-title":"Br J Cardiol"},{"key":"pone.0323137.ref033","author":"AstraZeneca Pharmaceuticals LP"},{"key":"pone.0323137.ref034","author":"European Medicines Agency"},{"issue":"14","key":"pone.0323137.ref035","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"SJ Connolly","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0323137.ref036","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1182\/blood.V124.21.4269.4269","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors","volume":"124","author":"M Crowther","year":"2014","journal-title":"Blood"},{"issue":"13","key":"pone.0323137.ref037","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Jr Milling TJ","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"pone.0323137.ref038","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29484","article-title":"Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage","volume":"69","author":"K Takasaki","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"pone.0323137.ref039","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology solution set oversight committee","volume":"76","author":"GF Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0323137.ref040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/anae.15181","article-title":"A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients","volume":"76","author":"G Erdoes","year":"2021","journal-title":"Anaesthesia"},{"issue":"2","key":"pone.0323137.ref041","article-title":"Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding","volume":"3","author":"AT Cohen","year":"2022","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"1","key":"pone.0323137.ref042","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13054-022-04043-8","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis","volume":"26","author":"OS Costa","year":"2022","journal-title":"Crit Care"},{"issue":"2","key":"pone.0323137.ref043","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/STROKEAHA.121.034572","article-title":"Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care","volume":"53","author":"HB Huttner","year":"2022","journal-title":"Stroke"},{"issue":"1","key":"pone.0323137.ref044","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","article-title":"Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate","volume":"56","author":"SS Sutton","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"pone.0323137.ref045","author":"TriNetX"},{"key":"pone.0323137.ref046","author":"US Department of Health and Human Services"},{"key":"pone.0323137.ref047","author":"US Department of Health and Human Services"},{"issue":"11","key":"pone.0323137.ref048","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008864","article-title":"Defining venous thromboembolism and measuring its incidence using Swedish health registries: a nationwide pregnancy cohort study","volume":"5","author":"A Abdul Sultan","year":"2015","journal-title":"BMJ Open"},{"key":"pone.0323137.ref049","article-title":"The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study","volume":"350","author":"M Jun","year":"2015","journal-title":"BMJ"},{"key":"pone.0323137.ref050","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/CLEP.S177058","article-title":"Positive predictive value and misclassification of diagnosis of pulmonary embolism and deep vein thrombosis in Swedish patient registries","volume":"10","author":"L \u00d6hman","year":"2018","journal-title":"Clin Epidemiol"},{"key":"pone.0323137.ref051","author":"The Dudley Group NHS Foundation Trust"},{"issue":"10283","key":"pone.0323137.ref052","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(21)00762-5","article-title":"Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?","volume":"397","author":"SD \u00d8stergaard","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"pone.0323137.ref053","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"J Halton","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"pone.0323137.ref054","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.rpth.2022.100001","article-title":"Direct oral anticoagulants in pediatric venous thromboembolism: experience in specialized pediatric hemostasis centers in the United States","volume":"7","author":"FF Corrales-Medina","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"pone.0323137.ref055","article-title":"Rivaroxaban treatment among children with cancer-associated thromboembolism: Real-world data","volume":"69","author":"AA Barg","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"pone.0323137.ref056","author":"US Food and Drug Administration"},{"issue":"6","key":"pone.0323137.ref057","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"J Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"issue":"6","key":"pone.0323137.ref058","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1055\/s-0038-1648971","article-title":"Thrombin regulation in children differs from adults in the absence and presence of heparin","volume":"72","author":"M Andrew","year":"1994","journal-title":"Thromb Haemost"},{"issue":"2","key":"pone.0323137.ref059","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2009.12.001","article-title":"Hemostasis in neonates and children: pitfalls and dilemmas","volume":"24","author":"P Monagle","year":"2010","journal-title":"Blood Rev"},{"issue":"6","key":"pone.0323137.ref060","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1177\/0962280216671348","article-title":"Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies","volume":"27","author":"C Petit","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"pone.0323137.ref061","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"MH Prins","year":"2013","journal-title":"Thromb J"},{"key":"pone.0323137.ref062","doi-asserted-by":"crossref","first-page":"10760296221078842","DOI":"10.1177\/10760296221078842","article-title":"Andexanet alfa versus prothrombin complex concentrates\/blood products as apixaban\/rivaroxaban reversal agents: a survey among pediatric hematologists","volume":"28","author":"V Rodriguez","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"pone.0323137.ref063","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1740774509339238","article-title":"Bayesian design using adult data to augment pediatric trials","volume":"6","author":"DA Schoenfeld","year":"2009","journal-title":"Clin Trials"},{"key":"pone.0323137.ref064","author":"Bayer"},{"key":"pone.0323137.ref065","author":"Bristol Myers Squibb"},{"key":"pone.0323137.ref066","author":"Bristol Myers Squibb"},{"key":"pone.0323137.ref067","author":"Bristol Myers Squibb"},{"key":"pone.0323137.ref068","author":"Indiana University"},{"key":"pone.0323137.ref069","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12959-018-0186-0","article-title":"Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study","volume":"16","author":"D Kubitza","year":"2018","journal-title":"Thromb J"},{"key":"pone.0323137.ref070","author":"Optum.com"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:34:49Z","timestamp":1746725689000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323137"}},"subtitle":[],"editor":[{"given":"Hideto","family":"Sano,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323137","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}